{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/BCAX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-15T17:25:40.023Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":5314,"canonical_name":"Bicara Therapeutics Inc.","cik":"0002023658","uei":null,"lei":null,"duns":null,"ticker":"BCAX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":66},"count":66,"timeline":[{"ts":"2026-09-10","kind":"sec.filing","form_type":"4","title":"4 — Bicara Therapeutics Inc. — 2026-09-10","url_slug":"/sec/cik-0002023658/4/0001470831-26-000883","accession_number":"0001470831-26-000883","importance":30},{"ts":"2026-09-08","kind":"sec.filing","form_type":"144","title":"144 — Bicara Therapeutics Inc. — 2026-09-08","url_slug":"/sec/cik-0002023658/144/0001969223-26-001008","accession_number":"0001969223-26-001008","importance":30},{"ts":"2026-09-08","kind":"sec.filing","form_type":"144","title":"144 — Bicara Therapeutics Inc. — 2026-09-08","url_slug":"/sec/cik-0002023658/144/0001969223-26-001009","accession_number":"0001969223-26-001009","importance":30},{"ts":"2026-08-25","kind":"sec.filing","form_type":"8-K","title":"8-K — Bicara Therapeutics Inc. — 2026-08-25","url_slug":"/sec/cik-0002023658/8-k/0001628280-26-058937","accession_number":"0001628280-26-058937","importance":35},{"ts":"2026-08-14","kind":"sec.filing","form_type":"3","title":"3 — Bicara Therapeutics Inc. — 2026-08-14","url_slug":"/sec/cik-0002023658/3/0001470831-26-000818","accession_number":"0001470831-26-000818","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"4","title":"4 — Bicara Therapeutics Inc. — 2026-08-14","url_slug":"/sec/cik-0002023658/4/0001470831-26-000819","accession_number":"0001470831-26-000819","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"4","title":"4 — Bicara Therapeutics Inc. — 2026-08-12","url_slug":"/sec/cik-0002023658/4/0001470831-26-000812","accession_number":"0001470831-26-000812","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"4","title":"4 — Bicara Therapeutics Inc. — 2026-08-12","url_slug":"/sec/cik-0002023658/4/0001470831-26-000813","accession_number":"0001470831-26-000813","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"4","title":"4 — Bicara Therapeutics Inc. — 2026-08-12","url_slug":"/sec/cik-0002023658/4/0001470831-26-000814","accession_number":"0001470831-26-000814","importance":30},{"ts":"2026-08-11","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Bicara Therapeutics Inc. — 2026-08-11","url_slug":"/sec/cik-0002023658/10-q/0001628280-26-055765","accession_number":"0001628280-26-055765","importance":45},{"ts":"2026-08-11","kind":"sec.filing","form_type":"8-K","title":"8-K — Bicara Therapeutics Inc. — 2026-08-11","url_slug":"/sec/cik-0002023658/8-k/0001628280-26-055500","accession_number":"0001628280-26-055500","importance":35},{"ts":"2026-08-11","kind":"sec.filing","form_type":"S-8","title":"S-8 — Bicara Therapeutics Inc. — 2026-08-11","url_slug":"/sec/cik-0002023658/s-8/0001628280-26-055779","accession_number":"0001628280-26-055779","importance":30},{"ts":"2026-08-10","kind":"sec.filing","form_type":"144","title":"144 — Bicara Therapeutics Inc. — 2026-08-10","url_slug":"/sec/cik-0002023658/144/0001969223-26-000869","accession_number":"0001969223-26-000869","importance":30},{"ts":"2026-08-10","kind":"sec.filing","form_type":"144","title":"144 — Bicara Therapeutics Inc. — 2026-08-10","url_slug":"/sec/cik-0002023658/144/0001969223-26-000872","accession_number":"0001969223-26-000872","importance":30},{"ts":"2026-08-10","kind":"sec.filing","form_type":"144","title":"144 — Bicara Therapeutics Inc. — 2026-08-10","url_slug":"/sec/cik-0002023658/144/0001969223-26-000873","accession_number":"0001969223-26-000873","importance":30},{"ts":"2026-07-28","kind":"sec.filing","form_type":"8-K","title":"8-K — Bicara Therapeutics Inc. — 2026-07-28","url_slug":"/sec/cik-0002023658/8-k/0001628280-26-049937","accession_number":"0001628280-26-049937","importance":35},{"ts":"2026-07-10","kind":"sec.insider.s","reporter":"Mazumdar Claire","title":"Chief Executive Officer","shares":9972,"price_per_share":28.4163,"usd_value":283367,"security_title":"Common Stock","importance":35.2833673436},{"ts":"2026-07-10","kind":"sec.insider.s","reporter":"Mazumdar Claire","title":"Chief Executive Officer","shares":28,"price_per_share":29.68,"usd_value":831,"security_title":"Common Stock","importance":35.00083104},{"ts":"2026-07-10","kind":"sec.filing","form_type":"144","title":"144 — Bicara Therapeutics Inc. — 2026-07-10","url_slug":"/sec/cik-0002023658/144/0001969223-26-000775","accession_number":"0001969223-26-000775","importance":30},{"ts":"2026-07-10","kind":"sec.filing","form_type":"4","title":"4 — Bicara Therapeutics Inc. — 2026-07-10","url_slug":"/sec/cik-0002023658/4/0001470831-26-000700","accession_number":"0001470831-26-000700","importance":30},{"ts":"2026-07-10","kind":"sec.filing","form_type":"4","title":"4 — Bicara Therapeutics Inc. — 2026-07-10","url_slug":"/sec/cik-0002023658/4/0001470831-26-000701","accession_number":"0001470831-26-000701","importance":30},{"ts":"2026-07-10","kind":"sec.insider.m","reporter":"Mazumdar Claire","title":"Chief Executive Officer","shares":10000,"price_per_share":3.7898,"usd_value":37898,"security_title":"Common Stock","importance":15.037898},{"ts":"2026-07-09","kind":"sec.insider.s","reporter":"Cohlhepp Ryan","title":"President and COO","shares":536,"price_per_share":29,"usd_value":15544,"security_title":"Common Stock","importance":35.015544},{"ts":"2026-07-08","kind":"sec.form144","reporter":"DAVID RABEN","title":"Officer","shares":50000,"usd_value":1428080,"security_title":"Common","approx_sale_date":"2026-07-08","accession_number":"0001950047-26-006962","importance":40.285616},{"ts":"2026-07-08","kind":"sec.form144","reporter":"Cohlhepp Ryan","title":"Officer, Director","shares":28750,"usd_value":869688,"security_title":"Common","approx_sale_date":"2026-07-08","accession_number":"0001969223-26-000773","importance":40.1739375},{"ts":"2026-07-08","kind":"sec.form144","reporter":"Hyep Ivan","title":"Officer","shares":28000,"usd_value":847000,"security_title":"Common","approx_sale_date":"2026-07-08","accession_number":"0001969223-26-000771","importance":40.1694},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Cohlhepp Ryan","title":"President and COO","shares":22833,"price_per_share":28.7589,"usd_value":656652,"security_title":"Common Stock","importance":35.6566519637},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Hyep Ivan","title":"Chief Financial Officer","shares":22757,"price_per_share":28.602,"usd_value":650896,"security_title":"Common Stock","importance":35.650895714},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Hyep Ivan","title":"Chief Financial Officer","shares":4413,"price_per_share":29.8246,"usd_value":131616,"security_title":"Common Stock","importance":35.1316159598},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Cohlhepp Ryan","title":"President and COO","shares":4306,"price_per_share":29.7961,"usd_value":128302,"security_title":"Common Stock","importance":35.1283020066},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Cohlhepp Ryan","title":"President and COO","shares":1075,"price_per_share":30.3549,"usd_value":32632,"security_title":"Common Stock","importance":35.0326315175},{"ts":"2026-07-08","kind":"sec.insider.s","reporter":"Hyep Ivan","title":"Chief Financial Officer","shares":830,"price_per_share":30.3136,"usd_value":25160,"security_title":"Common Stock","importance":35.025160288},{"ts":"2026-07-08","kind":"sec.filing","form_type":"144","title":"144 — Bicara Therapeutics Inc. — 2026-07-08","url_slug":"/sec/cik-0002023658/144/0001950047-26-006962","accession_number":"0001950047-26-006962","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"144","title":"144 — Bicara Therapeutics Inc. — 2026-07-08","url_slug":"/sec/cik-0002023658/144/0001969223-26-000771","accession_number":"0001969223-26-000771","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"144","title":"144 — Bicara Therapeutics Inc. — 2026-07-08","url_slug":"/sec/cik-0002023658/144/0001969223-26-000773","accession_number":"0001969223-26-000773","importance":30},{"ts":"2026-07-08","kind":"sec.insider.m","reporter":"Cohlhepp Ryan","title":"President and COO","shares":18750,"price_per_share":3.7898,"usd_value":71059,"security_title":"Common Stock","importance":15.07105875},{"ts":"2026-07-08","kind":"sec.insider.m","reporter":"Hyep Ivan","title":"Chief Financial Officer","shares":12500,"price_per_share":3.7898,"usd_value":47373,"security_title":"Common Stock","importance":15.0473725},{"ts":"2026-07-07","kind":"sec.form144","reporter":"Lara Meisner","title":"Officer","shares":1000,"usd_value":29774,"security_title":"Common","approx_sale_date":"2026-07-07","accession_number":"0001950047-26-006915","importance":40.0059548},{"ts":"2026-06-25","kind":"sec.form144","reporter":"DAVID RABEN","title":"Officer","shares":50000,"usd_value":1324650,"security_title":"Common","approx_sale_date":"2026-06-25","accession_number":"0001950047-26-006490","importance":40.26493},{"ts":"2026-06-25","kind":"sec.filing","form_type":"144","title":"144 — Bicara Therapeutics Inc. — 2026-06-25","url_slug":"/sec/cik-0002023658/144/0001950047-26-006490","accession_number":"0001950047-26-006490","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Bicara Therapeutics Inc. — 2026-06-10","url_slug":"/sec/cik-0002023658/8-k/0001628280-26-042176","accession_number":"0001628280-26-042176","importance":35},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Simson Jake — 2026-06-10","url_slug":"/sec/cik-0001863094/4/0001628280-26-042247","accession_number":"0001628280-26-042247","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Bicara Therapeutics Inc. — 2026-06-10","url_slug":"/sec/cik-0002023658/4/0001628280-26-042251","accession_number":"0001628280-26-042251","importance":30},{"ts":"2026-06-01","kind":"sec.form144","reporter":"Meisner Lara","title":"Former Chief Legal Officer","shares":71390,"usd_value":1473716,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001883986-26-000002","importance":40.294743292},{"ts":"2026-05-21","kind":"sec.form144","reporter":"Hyep Ivan","title":"Officer","shares":9200,"usd_value":187883,"security_title":"Common","approx_sale_date":"2026-05-21","accession_number":"0001969223-26-000585","importance":40.037576664},{"ts":"2026-05-21","kind":"sec.filing","form_type":"8-K","title":"8-K — Bicara Therapeutics Inc. — 2026-05-21","url_slug":"/sec/cik-0002023658/8-k/0001628280-26-037377","accession_number":"0001628280-26-037377","importance":35},{"ts":"2026-05-21","kind":"sec.filing","form_type":"144","title":"144 — Bicara Therapeutics Inc. — 2026-05-21","url_slug":"/sec/cik-0002023658/144/0001969223-26-000585","accession_number":"0001969223-26-000585","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Bicara Therapeutics Inc. — 2026-05-20","url_slug":"/sec/cik-0002023658/4/0001628280-26-036885","accession_number":"0001628280-26-036885","importance":30},{"ts":"2026-05-18","kind":"sec.form144","reporter":"Mazumdar Claire","title":"Officer, Director","shares":15000,"usd_value":313800,"security_title":"Common","approx_sale_date":"2026-05-18","accession_number":"0001969223-26-000564","importance":40.06276},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Mazumdar Claire","title":"Chief Executive Officer","shares":12022,"price_per_share":19.9619,"usd_value":239982,"security_title":"Common Stock","importance":35.2399819618},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Mazumdar Claire","title":"Chief Executive Officer","shares":2978,"price_per_share":20.3481,"usd_value":60597,"security_title":"Common Stock","importance":35.0605966418},{"ts":"2026-05-18","kind":"sec.filing","form_type":"144","title":"144 — Bicara Therapeutics Inc. — 2026-05-18","url_slug":"/sec/cik-0002023658/144/0001969223-26-000564","accession_number":"0001969223-26-000564","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"4","title":"4 — Bicara Therapeutics Inc. — 2026-05-18","url_slug":"/sec/cik-0002023658/4/0001628280-26-035937","accession_number":"0001628280-26-035937","importance":30},{"ts":"2026-05-18","kind":"sec.insider.m","reporter":"Mazumdar Claire","title":"Chief Executive Officer","shares":15000,"price_per_share":3.7898,"usd_value":56847,"security_title":"Common Stock","importance":15.056847},{"ts":"2026-05-15","kind":"sec.form144","reporter":"Cohlhepp Ryan","title":"Officer, Director","shares":12500,"usd_value":253875,"security_title":"Common","approx_sale_date":"2026-05-15","accession_number":"0001969223-26-000560","importance":40.050775},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"Cohlhepp Ryan","title":"President and COO","shares":8000,"price_per_share":20.2919,"usd_value":162335,"security_title":"Common Stock","importance":35.1623352},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"Cohlhepp Ryan","title":"President and COO","shares":4500,"price_per_share":20.2919,"usd_value":91314,"security_title":"Common Stock","importance":35.09131355},{"ts":"2026-05-15","kind":"sec.filing","form_type":"144","title":"144 — Bicara Therapeutics Inc. — 2026-05-15","url_slug":"/sec/cik-0002023658/144/0001969223-26-000560","accession_number":"0001969223-26-000560","importance":30},{"ts":"2026-05-15","kind":"sec.insider.m","reporter":"Cohlhepp Ryan","title":"President and COO","shares":8000,"price_per_share":3.7898,"usd_value":30318,"security_title":"Common Stock","importance":15.0303184},{"ts":"2026-05-12","kind":"sec.filing","form_type":"3","title":"3 — Bicara Therapeutics Inc. — 2026-05-12","url_slug":"/sec/cik-0002023658/3/0001628280-26-034079","accession_number":"0001628280-26-034079","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"4","title":"4 — Bicara Therapeutics Inc. — 2026-05-12","url_slug":"/sec/cik-0002023658/4/0001628280-26-034087","accession_number":"0001628280-26-034087","importance":30},{"ts":"2026-04-27","kind":"sec.form144","reporter":"Raben David","title":"Officer","shares":5500,"usd_value":125830,"security_title":"Common","approx_sale_date":"2026-04-27","accession_number":"0001969223-26-000470","importance":40.025166002},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — Bicara Therapeutics Inc. — 2026-04-27","url_slug":"/sec/cik-0002023658/def-14a/0001628280-26-027320","accession_number":"0001628280-26-027320","importance":40},{"ts":"2026-04-27","kind":"sec.filing","form_type":"144","title":"144 — Bicara Therapeutics Inc. — 2026-04-27","url_slug":"/sec/cik-0002023658/144/0001969223-26-000470","accession_number":"0001969223-26-000470","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"ARS","title":"ARS — Bicara Therapeutics Inc. — 2026-04-27","url_slug":"/sec/cik-0002023658/ars/0001628280-26-027322","accession_number":"0001628280-26-027322","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Bicara Therapeutics Inc. — 2026-04-27","url_slug":"/sec/cik-0002023658/defa14a/0001628280-26-027321","accession_number":"0001628280-26-027321","importance":30}]}